Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

CLOTBUST Hands-Free: A Phase I/II Pilot Safety Trial (CLOTBUST-HF)

This study has been completed.
Sponsor:
Collaborator:
University of Alabama at Birmingham
Information provided by (Responsible Party):
James Grotta, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT01240356
First received: November 8, 2010
Last updated: May 17, 2016
Last verified: May 2016
  Purpose
The purpose of CLOTBUST-HF is to determine the safety of a novel, external Hands-Free transcranial Doppler (TCD) ultrasound system in healthy volunteers and ischemic stroke patients. If found to be safe, the widespread use of operator-independent, ultrasound-enhanced thrombolysis will allow the planning for a large Phase III efficacy trial.

Condition Intervention Phase
Stroke
Device: 2-MHz transcranial Doppler ultrasound
Device: 2-MHz transcranial Doppler ultrasound insonation
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Combined Lysis of Thrombus in Brain Ischemia With Transcranial Ultrasound and Systemic T-PA-Hands-Free. A Phase I/II Pilot Safety Trial

Resource links provided by NLM:


Further study details as provided by The University of Texas Health Science Center, Houston:

Primary Outcome Measures:
  • Number of Participants in Phase I Group With Blood-brain-barrier Disruption (BBB) as Measured by MRI of the Brain [ Time Frame: 2-3 hours after treatment ] [ Designated as safety issue: Yes ]
    Phase I : Imaging of the brain via MRI scans was performed to determine if the Hands-Free transcranial Doppler (TCD) system results in any BBB-disruption or deterioration in permeability.

  • Safety in Phase II Group as Measured by Incidence of Symptomatic Intracerebral Hemorrhage [ Time Frame: within 24 hours ] [ Designated as safety issue: Yes ]
    Phase II: Determine if the Hands-Free TCD will not result in higher than 10% rate of symptomatic intracerebral hemorrhage (ICH) within 24 hours (defined as clinical worsening > 4 NIH Stroke Scale (NIHSS) points and presence of hemorrhage on CT scan that in the opinion of the treating physician is causatively related to ICH on CT) in 0-3 hours acute stroke patients treated with intravenous tissue-type plasminogen activator (IV-t-PA).

  • Number of Participants in Phase I Group With Neurological Deterioration as Measured by Neurological Examination [ Time Frame: 2-3 hours after treatment ] [ Designated as safety issue: Yes ]
    The neurological examinations comprised assessments of mental status and orientation, cranial nerve examination, muscle strength and tone, deep tendon reflexes, sensory testing, coordination, and gait.


Secondary Outcome Measures:
  • Number of Participants in Phase I Group With Adverse Events During and After Study Treatment With HF TCD [ Time Frame: 2-3 hours after treatment ] [ Designated as safety issue: Yes ]
    Phase I - A group of healthy volunteers will be assessed to determine the feasibility and activity of hands-free (HF) transcranial Doppler (TCD). Adverse events include subject complaints regarding discomfort of the device and dermatological adverse events as evidenced by a detailed physical examination of skin integrity post-insonation.

  • Percentage of Participants in the Phase II Group That Show Arterial Recanalization as Measured Using Standard Transcranial Doppler Ultrasound Systems [ Time Frame: 2-3 hours after treatment ] [ Designated as safety issue: No ]
    Ischemic stroke patients: 2-hour rates of arterial complete and partial recanalization as measured using standard Transcranial Doppler Ultrasound systems.

  • Percentage of Participants in Phase II Group With Neurological Worsening as Determined by the NIH Stroke Scale [ Time Frame: within 90 days of enrollment ] [ Designated as safety issue: Yes ]
    The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. Each item on the NIHSS scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.

  • Percentage of Participants in Phase II Group With Excellent Outcome as Measured by Modified Rankin Scale (mRS) [ Time Frame: at 3-months from enrollment ] [ Designated as safety issue: No ]
    A modified Rankin Scale (mRS) score of 0 or 1 indicates an excellent outcome. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The mRS scale ranks patients from 0 to 6 (0 is the best score, 6 is the worst score).


Enrollment: 35
Study Start Date: December 2008
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Phase I: Healthy Volunteers
Subjects without history of Central Nervous System Disease will receive 2-hours of hands-free 2-megahertz (MHz) transcranial Doppler ultrasound insonation continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
Device: 2-MHz transcranial Doppler ultrasound
2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
Other Names:
  • transcranial Doppler Ultrasound
  • ultrasound
Experimental: Phase II: 0-3 hour Patients
Ischemic stroke patients who present between 0-3 hours will receive 2-hours of hands-free 2-MHz transcranial Doppler ultrasound Continuously to the intracranial vessels.
Device: 2-MHz transcranial Doppler ultrasound insonation
2-hours of hands-free ultrasound delivered to in the intracranial vessels.
Other Names:
  • transcranial Doppler ultrasound
  • ultrasound
  • sonothrombolysis

Detailed Description:

Ultrasound energy to enhance intravenous rt-PA thrombolysis is a promising novel treatment modality for ischemic stroke. Despite encouraging safety data utilizing diagnostic frequencies of transcranial Doppler (TCD) ultrasound, lack of widespread availability of trained personnel has limited its application.

- The primary specific aim for this pilot phase I/II study is to assess the safety of a novel, external Hands-Free TCD ultrasound system. Safety of the new Hands-Free TCD system will first be assessed in healthy volunteers. Safety in these participants will be determined by detailed neurological and dermatological exams and MRI imaging of the brain. Next, safety of the device will be evaluated in two distinct sets of acute ischemic stroke patients: 0-3 hour patients treated with standard IV rt-PA and 3-6 hour non-lytic, image-selected patients treated with sonolysis (with or without intravenous microbubbles). Among the healthy volunteers the primary measures of safety will be to have no detectable changes in a detailed neurological exam nor any blood- brain barrier (BBB) disruption or changes in permeability. Among both the 0-3 hour and 3-6 hour groups the primary measure of safety will be to not tolerate greater than a 10% rate of symptomatic intracerebral hemorrhage (sICH) within 24 hours.

* The primary hypothesis is that replacing conventional TCD ultrasound hand-held TCD technology with a Hands-Free system will be safe in healthy volunteers as well as acute ischemic stroke patients.

If the device is found to be safe in either the 0-3 hour or 3-6 hour groups,

- the secondary aims for this study will explore the rates of arterial recanalization in the 0-3 hour and/or 3-6 hour groups, favorable outcomes, and clinical recovery. The secondary aims will assess the hypothesis is that Hands-Free TCD will display similar recanalization and early clinical recovery rates compared to available historical diagnostic TCD ultrasound controls exposed to conventional FDA-approved TCD technology.

Data generated during this phase I/II trial will evaluate the safety of replacing an operator-dependent TCD device with an operator-independent unit. In turn, this will allow extensive availability of therapeutic ultrasound and improve enrollment into ultrasound-enhanced thrombolysis stroke trials.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

INCLUSION CRITERIA:

Phase I Safety (healthy volunteers):

  • Presence of temporal windows as measured first by an FDA-approved diagnostic TCD device.
  • Age ≥ 18 years old.
  • Signed informed consent.

Phase II (0-3 hours ischemic stroke patients):

  • Disabling focal neurological deficit (NIHSS > 4 points);
  • No evidence of hemorrhage on non-contrast head CT scan;
  • Intravenous rt-PA (0.9 mg/kg, 10% bolus 90% infusion over 1 hour, maximum dose 90 mg) infusion initiated within 3 hours of symptom onset;
  • Diagnostic TCD completed and HF-TCD placed before rt-PA bolus.
  • Diagnostic TCD confirms intracranial arterial occlusion of the middle cerebral artery (MCA), anterior cerebral artery (ACA), internal carotid artery (ICA), posterior cerebral artery (PCA) or distal basilar artery.
  • Age ≥ 18 years old.
  • Signed informed consent.

Phase II (3-6 hours ischemic stroke patients):

  • Measurable focal neurological deficit (NIHSS > 4 points);
  • No evidence of hemorrhage on non-contrast head CT scan;
  • Diagnostic TCD confirms intracranial arterial occlusion of the middle cerebral artery (MCA), anterior cerebral artery (ACA), internal carotid artery (ICA), posterior cerebral artery (PCA) or distal basilar artery.
  • Presence of neuroimaging defined mismatch (CT or MRI prior to enrollment)

    1. CT-perfusion

      • ≥ 20% difference between affected territories on Time to Peak (TTP) and Cerebral Blood Volume (CBV) maps.
    2. MRI Diffusion-Perfusion mismatch

      • ≥ 20% difference between diffusion-weighted imaging (DWI) lesion and territory of perfusion delay perfusion weighted imaging (PWI).
  • Age ≥ 18 years old.
  • Signed informed consent.

EXCLUSION CRITERIA:

Phase I Safety (healthy volunteers):

  • History of any neurological disease affecting the central nervous system;
  • Lack of temporal windows.
  • History of renal disease or glomerular filtration rate (GFR) < 60.
  • Contraindication to MRI (e.g., pacemaker, spinal cord stimulator, severe claustrophobia)

Phase II (0-3 hours ischemic stroke patients):

  • Absent temporal windows in patients with anterior circulation ischemia;
  • Intra-arterial thrombolysis;
  • Patient refusal to give informed consent to participate in the CLOTBUST-HF trial;
  • Contraindications for intravenous rt-PA (NINDS rt-PA Stroke Study Protocol)2.
  • Phase II (3-6 hours ischemic stroke patients):
  • Absent temporal windows in patients with anterior circulation ischemia;
  • Intra-arterial thrombolysis;
  • Patient refusal to give informed consent to participate in the CLOTBUST-HF trial;
  • History of allergic response to Definity® microspheres or microbubbles currently being tested (MRX-801);
  • Baseline imaging consistent with a malignant ischemic pattern (low CBV values or DWI territory >100cc of tissue);
  • Baseline MRI imaging demonstrating delayed perfusion of > 8 seconds in >100cc of brain parenchyma26;
  • Patients receiving other investigational drugs, procedures, or therapies within 30 days prior to study treatment;
  • Significant concurrent medical/neurological conditions or deviation from normal laboratory test values at baseline that, in the opinion of the investigator, pose significant risk to the patient and warrant exclusion from the study;
  • Known severe chronic obstructive pulmonary disease (COPD) (baseline oxygen saturation < 80% on room air);
  • Known right-to-left cardiac shunt.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01240356

Locations
United States, Alabama
University of Alabama Birmingham
Birmingham, Alabama, United States, 35233
United States, Texas
UT Medical School-Houston
Houston, Texas, United States, 77030
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
University of Alabama at Birmingham
Investigators
Principal Investigator: James C. Grotta, MD UT Medical School-Houston
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: James Grotta, MD, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT01240356     History of Changes
Other Study ID Numbers: CLOTBUST-HF 
Study First Received: November 8, 2010
Results First Received: January 27, 2014
Last Updated: May 17, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by The University of Texas Health Science Center, Houston:
transcranial doppler
sonothrombolysis
ultrasound
stroke

ClinicalTrials.gov processed this record on December 06, 2016